HUP0004148A2 - Farnezil-protein transzferáz inhibitorok - Google Patents
Farnezil-protein transzferáz inhibitorokInfo
- Publication number
- HUP0004148A2 HUP0004148A2 HU0004148A HUP0004148A HUP0004148A2 HU P0004148 A2 HUP0004148 A2 HU P0004148A2 HU 0004148 A HU0004148 A HU 0004148A HU P0004148 A HUP0004148 A HU P0004148A HU P0004148 A2 HUP0004148 A2 HU P0004148A2
- Authority
- HU
- Hungary
- Prior art keywords
- ncn
- groups
- cyano
- aryl
- heterocyclo
- Prior art date
Links
- 102000004357 Transferases Human genes 0.000 title abstract 2
- 108090000992 Transferases Proteins 0.000 title abstract 2
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 101100495912 Arabidopsis thaliana CHR12 gene Proteins 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 101150020251 NR13 gene Proteins 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- -1 heterocyclo Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000013498 protein farnesylation Effects 0.000 abstract 1
- 102000016914 ras Proteins Human genes 0.000 abstract 1
- 108010014186 ras Proteins Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány a farnezil-protein transzferázt és a ras proteinfarnezileződését gátló, és ennek révén rákellenes hatóanyagokkéntalkalmazható (I) és (II) általános képletű vegyületekre - amelyekképletében l, m, r, s és t 0 vagy 1; n 0, 1 vagy 2; Y SO2, SO3, CO,CO2, O, C (NCN), CHR12, NR13, SO2NR14, CONR15, C (NCN)NR16, NR17CO,NR18SO2, CONR19NR20, SO2NR21NR22, S(O)(NR23), S(NR24) (NR25) csoport,vagy Y nincs jelen; Z S, SO, SO2, SO3, CO, CO2, O, CR12, NR13,SO2NR14, CONR15, NR26NR27, ONR28, NR29O, NR30SO2NR31, NR32SO2, NR33C(NCN), NR34C (NCN) NR35, NR36CO, NR37CONR38, NR39CO2, OCONR40, S (O)(NR41)m S(NR42) (NR43), CHR12 csoport vagy Z nincs jelen; R7 és R8hidrogén-, halogénatom, nitro-, ciano-, U-R44 csoport; U S, O, CO, SO,SO2, CO2, NR45, NR46CO2, NR47CONR48, NR49SO2, NR50SO2NR51, SO2NR52NR53CO CONR54, PO2R55, PO3R56 csoport, vagy U nincs jelen; R9, R10,R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25,R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39,R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54,R55, R56, R57, R58 és R59 hidrogénatom, adott esetben szubsztituáltalkil-, aril-, heterociklocsoport; R11 és R14 hidrogénatom, adottesetben alkil-, alkenil-, alkinil-, aralkil-, cikloalkil-, aril-,heterociklocsoport; Rl, R2, R3, R4, R5 és R6 hidrogénatom, adottesetben szubsztituált alkil-, alkenil-, alkinil-, aralkil-,cikloalkil-, aril-, heterociklo-, ciano-, karboxi-, adott esetbenszubsztituált karbamoilcsoport, alkoxi-karbonil-csoport; ahol R1, R2,R3, R4, R5 és R6 közül kettő cikloalkilcsoportot vagy oxocsoportot; R,S és T CH2, CO vagy CH(CH2)pQ csoport, ahol Q NR57R58, OR59 vagycianocsoport; és p 0, 1 vagy 2; A, B és C szén-, oxigén-, kén- vagynitrogénatom; D szén-, oxigén-, kén-, nitrogénatom, vagy D nincs jelen; aleírásban meghatározott megkötésekkel - és enantiomereikre,diasztereomereikre, gyógyszerészetileg elfogadható sóikra,prodrogjaikra és szolvátjaikra vonatkozik. A találmány kiterjed atalálmány szerinti vegyületeket tartalmazó gyógyszerkészítményekre,valamint a vegyületek gyógyászati felhasználására is. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5159497P | 1997-07-02 | 1997-07-02 | |
| PCT/US1998/012549 WO1999001434A1 (en) | 1997-07-02 | 1998-06-16 | Inhibitors of farnesyl protein transferase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0004148A2 true HUP0004148A2 (hu) | 2001-10-28 |
| HUP0004148A3 HUP0004148A3 (en) | 2002-09-30 |
Family
ID=21972255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0004148A HUP0004148A3 (en) | 1997-07-02 | 1998-06-16 | Inhibitors of farnesyl protein transferase |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6387926B1 (hu) |
| EP (1) | EP0994856A4 (hu) |
| JP (1) | JP2002507989A (hu) |
| KR (1) | KR100385941B1 (hu) |
| CN (1) | CN1261880A (hu) |
| AR (1) | AR016304A1 (hu) |
| AU (1) | AU734721B2 (hu) |
| BR (1) | BR9810465A (hu) |
| CA (1) | CA2294530A1 (hu) |
| CO (1) | CO4950556A1 (hu) |
| HU (1) | HUP0004148A3 (hu) |
| ID (1) | ID24076A (hu) |
| IL (1) | IL133470A0 (hu) |
| MY (1) | MY117961A (hu) |
| NO (1) | NO316117B1 (hu) |
| NZ (1) | NZ501293A (hu) |
| PE (1) | PE86599A1 (hu) |
| PL (1) | PL337697A1 (hu) |
| RU (1) | RU2211838C2 (hu) |
| TR (1) | TR199903331T2 (hu) |
| TW (1) | TW527355B (hu) |
| UY (1) | UY25074A1 (hu) |
| WO (1) | WO1999001434A1 (hu) |
| ZA (1) | ZA985778B (hu) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2340100A1 (en) * | 1998-08-11 | 2000-02-24 | Daiichi Pharmaceutical Co., Ltd. | Novel sulfonyl derivatives |
| EP1109544A4 (en) * | 1998-09-01 | 2004-10-27 | Bristol Myers Squibb Co | POTASSIUM CHANNEL INHIBITORS AND THEIR METHOD OF USE |
| US6316436B1 (en) | 1998-12-08 | 2001-11-13 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| NZ519380A (en) | 1999-12-28 | 2004-10-29 | Eisai Co Ltd | Heterocyclic compounds having sulfonamide groups |
| GB0023915D0 (en) * | 2000-09-29 | 2000-11-15 | Inst Of Ophthalmology | Treatment of neuroinflammatory disease |
| US20040044032A1 (en) * | 2000-11-28 | 2004-03-04 | End David William | Farnesyl protein transfer inhibitors for the treatment of inflammatory bowel disease |
| FR2819510B1 (fr) * | 2001-01-18 | 2003-10-31 | Servier Lab | Nouveaux composes cyclo[c] azepane, leur procede de preparation et les compositions pharmaceutiques qui le contiennent |
| FR2819512B1 (fr) * | 2001-01-18 | 2003-02-21 | Servier Lab | Nouveaux composes cyclo[d] azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| US6740757B2 (en) * | 2001-08-29 | 2004-05-25 | Pfizer Inc | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| EP1534862A4 (en) * | 2002-08-07 | 2007-10-10 | Exelixis Inc | RABGGT MODULATORS AND METHODS OF USE THEREOF |
| FR2844273B1 (fr) | 2002-09-05 | 2008-04-04 | Aventis Pharma Sa | Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens. |
| EP4059923A1 (en) * | 2002-11-20 | 2022-09-21 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| US7276608B2 (en) * | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US7517890B2 (en) | 2003-11-20 | 2009-04-14 | Children's Hospital Medical Center | GTPase inhibitors and methods of use |
| US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
| EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | TREATMENT OF SYNUCLEINOPATHIES |
| CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| US7531554B2 (en) * | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| US20060160850A1 (en) * | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| WO2006101937A1 (en) | 2005-03-18 | 2006-09-28 | Janssen Pharmaceutica N.V. | Acylhydrazones as kinase modulators |
| JP5258561B2 (ja) | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ， インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
| CA2617056A1 (en) | 2005-07-29 | 2007-02-08 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
| US8003624B2 (en) * | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| WO2007075923A2 (en) * | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Treatment of synucleinopathies |
| PL1992607T3 (pl) * | 2006-03-06 | 2015-05-29 | Japan Tobacco Inc | Sposób wytwarzania związku 4-oksochinolinowego |
| WO2007145704A2 (en) * | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
| RU2456281C2 (ru) * | 2006-11-16 | 2012-07-20 | Ф. Хоффманн-Ля Рош Аг | Замещенные 4-имидазолы, способ их получения и их применение |
| EA017308B1 (ru) * | 2007-05-10 | 2012-11-30 | Олбани Молекьюлар Рисерч, Инк. | Арилокси- и гетероарилоксизамещенные тетрагидробензазепины и их применение для блокировки обратного захвата норэпинефрина, допамина и серотонина |
| FR2920773B1 (fr) * | 2007-09-11 | 2009-10-23 | Servier Lab | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2009079765A1 (en) * | 2007-12-21 | 2009-07-02 | Cascade Therapeutics Inc. | Compounds with activity at the 5-ht2c receptor |
| WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| BRPI0920927A2 (pt) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| WO2013064231A1 (en) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
| CN103864765B (zh) * | 2014-03-05 | 2016-02-10 | 天津药物研究院 | 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途 |
| US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
| US9957279B2 (en) | 2016-05-05 | 2018-05-01 | Laurus Labs Limited | Process for the preparation of intermediates useful in the preparation of Hepatitis C virus (HCV) inhibitors |
| WO2017213210A1 (ja) * | 2016-06-10 | 2017-12-14 | 武田薬品工業株式会社 | 複素環化合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110536A (en) | 1977-04-18 | 1978-08-29 | Miles Laboratories, Inc. | Derivatives of 5-(indol-3-yl)hydantoin |
| JPS5852256A (ja) * | 1981-09-24 | 1983-03-28 | Nippon Nohyaku Co Ltd | 置換又は非置換脂肪酸アミド誘導体及びその塩類 |
| JPS60222479A (ja) * | 1984-04-20 | 1985-11-07 | Nippon Tokushu Noyaku Seizo Kk | テトラヒドロキノリン―１―イルカルボニルイミダゾール誘導体、その製法並びに除草又は農園芸用殺菌剤 |
| US4576957A (en) | 1984-07-05 | 1986-03-18 | American Cyanamid Company | N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas |
| JPS6160682A (ja) * | 1984-08-30 | 1986-03-28 | Nippon Tokushu Noyaku Seizo Kk | テトラヒドロキノリン−１−イルカルボニルイミダゾ−ル誘導体、その中間体、それらの製法並びに除草又は農園芸用殺菌剤 |
| JPS6168487A (ja) * | 1984-09-12 | 1986-04-08 | Sumitomo Chem Co Ltd | カルバモイルアゾール誘導体およびそれを有効成分とする除草剤 |
| US5017584A (en) | 1984-12-20 | 1991-05-21 | Sterling Drug Inc. | Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas |
| JPS61227506A (ja) * | 1985-04-01 | 1986-10-09 | Nippon Tokushu Noyaku Seizo Kk | カルバモイルイミダゾ−ル類、その中間体、それらの製法並びに除草剤又は農園芸用殺菌剤 |
| JPS61280408A (ja) * | 1985-06-03 | 1986-12-11 | Sumitomo Chem Co Ltd | たばこ腋芽抑制剤 |
| JPS63270678A (ja) * | 1987-04-30 | 1988-11-08 | Mitsui Petrochem Ind Ltd | 新規含窒素化合物 |
| JP2652249B2 (ja) | 1989-08-22 | 1997-09-10 | 進 根本 | キーのつまみ部カバー |
| US5374615A (en) | 1990-10-31 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives |
| EP0485890A3 (en) * | 1990-11-16 | 1992-07-08 | Hoechst Aktiengesellschaft | Use of 2,3-disubstituate 1-azolyl-propane for inhibiting the pathogenic growth phase of dimorph yeast cell |
| US5633376A (en) | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
| US5371227A (en) | 1991-10-28 | 1994-12-06 | Synthelabo | Quinoline derivatives, process for their preparation, and their therapeutic applications |
| US5322950A (en) | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
| US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| US5726197A (en) | 1992-11-02 | 1998-03-10 | Syntex (U.S.A.) Inc. | Isoindolinyl derivatives |
| US5284841A (en) | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| CA2118985A1 (en) | 1993-04-02 | 1994-10-03 | Dinesh V. Patel | Heterocyclic inhibitors of farnesyl protein transferase |
| US5523317A (en) | 1993-07-05 | 1996-06-04 | Nippon Chemiphar Co., Ltd. | Method of reducing blood pressure |
| US5576437A (en) | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
| CA2179264C (en) | 1993-12-17 | 1999-05-18 | Thomas Lee Cupps | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| HUT72440A (en) * | 1994-03-31 | 1996-04-29 | Bristol Myers Squibb Co | Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them |
| US5607939A (en) | 1994-04-28 | 1997-03-04 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
| US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| TW436484B (en) | 1996-04-24 | 2001-05-28 | Dev Center Biotechnology | 1,2,3,4-tetrahydroisoquinoline derivatives having a nitrogen-containing heterocyclic methyl substituent, the preparation process and pharmaceutical composition thereof |
| WO1998002432A1 (en) | 1996-07-16 | 1998-01-22 | Takeda Chemical Industries, Ltd. | Bicyclic compounds for controlling micturition |
| UA60311C2 (uk) | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
-
1998
- 1998-05-26 TW TW087108171A patent/TW527355B/zh not_active IP Right Cessation
- 1998-05-29 US US09/087,179 patent/US6387926B1/en not_active Expired - Lifetime
- 1998-06-16 BR BR9810465-9A patent/BR9810465A/pt not_active IP Right Cessation
- 1998-06-16 NZ NZ501293A patent/NZ501293A/en unknown
- 1998-06-16 TR TR1999/03331T patent/TR199903331T2/xx unknown
- 1998-06-16 EP EP98930299A patent/EP0994856A4/en not_active Withdrawn
- 1998-06-16 IL IL13347098A patent/IL133470A0/xx unknown
- 1998-06-16 HU HU0004148A patent/HUP0004148A3/hu unknown
- 1998-06-16 KR KR10-1999-7012368A patent/KR100385941B1/ko not_active IP Right Cessation
- 1998-06-16 AU AU79719/98A patent/AU734721B2/en not_active Ceased
- 1998-06-16 RU RU2000102355/04A patent/RU2211838C2/ru not_active IP Right Cessation
- 1998-06-16 CA CA002294530A patent/CA2294530A1/en not_active Abandoned
- 1998-06-16 WO PCT/US1998/012549 patent/WO1999001434A1/en not_active Application Discontinuation
- 1998-06-16 PL PL98337697A patent/PL337697A1/xx unknown
- 1998-06-16 JP JP50718899A patent/JP2002507989A/ja not_active Ceased
- 1998-06-16 CN CN98806818A patent/CN1261880A/zh active Pending
- 1998-06-26 PE PE1998000565A patent/PE86599A1/es not_active Application Discontinuation
- 1998-06-26 MY MYPI98002919A patent/MY117961A/en unknown
- 1998-06-30 UY UY25074A patent/UY25074A1/es not_active IP Right Cessation
- 1998-07-01 CO CO98037149A patent/CO4950556A1/es unknown
- 1998-07-01 ZA ZA9805778A patent/ZA985778B/xx unknown
- 1998-07-02 AR ARP980103223A patent/AR016304A1/es unknown
-
1999
- 1999-06-16 ID IDW991728A patent/ID24076A/id unknown
- 1999-12-30 NO NO19996571A patent/NO316117B1/no unknown
-
2000
- 2000-05-05 US US09/566,396 patent/US6602883B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0994856A4 (en) | 2000-12-06 |
| TR199903331T2 (xx) | 2000-06-21 |
| BR9810465A (pt) | 2002-04-16 |
| NO316117B1 (no) | 2003-12-15 |
| KR20010014258A (ko) | 2001-02-26 |
| AR016304A1 (es) | 2001-07-04 |
| NO996571D0 (no) | 1999-12-30 |
| MY117961A (en) | 2004-08-30 |
| CN1261880A (zh) | 2000-08-02 |
| UY25074A1 (es) | 2000-12-29 |
| HUP0004148A3 (en) | 2002-09-30 |
| KR100385941B1 (ko) | 2003-06-09 |
| CO4950556A1 (es) | 2000-09-01 |
| PE86599A1 (es) | 1999-11-28 |
| IL133470A0 (en) | 2001-04-30 |
| JP2002507989A (ja) | 2002-03-12 |
| US6387926B1 (en) | 2002-05-14 |
| ID24076A (id) | 2000-07-06 |
| EP0994856A1 (en) | 2000-04-26 |
| NO996571L (no) | 2000-02-23 |
| CA2294530A1 (en) | 1999-01-14 |
| ZA985778B (en) | 2000-01-20 |
| US6602883B1 (en) | 2003-08-05 |
| RU2211838C2 (ru) | 2003-09-10 |
| AU734721B2 (en) | 2001-06-21 |
| TW527355B (en) | 2003-04-11 |
| PL337697A1 (en) | 2000-08-28 |
| AU7971998A (en) | 1999-01-25 |
| NZ501293A (en) | 2001-10-26 |
| WO1999001434A1 (en) | 1999-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0004148A2 (hu) | Farnezil-protein transzferáz inhibitorok | |
| AR030432A1 (es) | Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. | |
| AR037881A1 (es) | Uso de derivados de oxindol | |
| AR015774A1 (es) | Derivados de epotilona 12,13-modificados y sus sales | |
| MY114444A (en) | Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl -2-quinolone derivatives | |
| PT1263730E (pt) | Derivados amina para o tratamento de apoptose | |
| AR045691A1 (es) | Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos | |
| SV2003000876A (es) | Quinazolinas como inhibidores de mmp-13 | |
| GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
| ATE206611T1 (de) | Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung | |
| PT1280797E (pt) | Inibidores da peptidase iv de dipeptidilo | |
| CA2290992A1 (en) | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation | |
| TR200001279T2 (tr) | Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler. | |
| GEP20012413B (en) | Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents | |
| ES2151055T3 (es) | Derivados de l-n6-(1-iminoetil)lisina utiles como inhibidores de oxido nitrico sintasa. | |
| BRPI0506622A (pt) | éster biciclo derivado; um intermediário na produção do éster biciclo derivado; produto farmacêutico contendo um ingrediente ativo do éster biciclo derivado; inibidor dpp-iv contendo um ingrediente ativo do éster biciclo derivado; agente terapêutico para uma doença envolvendo dpp-iv contendo um ingrediente ativo do éster biciclo derivado, e agente terapêutico | |
| HUP0203054A2 (hu) | Farnezil protein transzferáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| DK1224940T3 (da) | Flydende formuleringer af interferon-beta | |
| MX9300988A (es) | Agentes antineoplasticos de quinobenzoxazina, quinobenzotiazina y pirido-acridina y composicion farmaceutica que los contiene. | |
| NO20014529D0 (no) | Tetrahydropyranderivater og deres anvendelse som terapautiske midler | |
| TR200000414T2 (tr) | 2-(4-Aril ya da heteroaril-piperazin-1-ilmetil)-1H-indol türevleri. | |
| DZ1694A1 (fr) | "n-(2-Aminoethyl)-benzothialozones". | |
| HUP0100760A2 (hu) | 2-Aril-etil-(piperidin-4-il-metil)-amin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| ES2081747B1 (es) | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. | |
| AR043741A1 (es) | 4-feniltetrahidroisoquinoleinas sustituidas, su uso como un medicamento, y el medicamento que las comprende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |